CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim

Cancer Research and Treatment. 2020;52(2):374-387. Published online 2019 August 13 DOI: https://doi.org/10.4143/crt.2019.198

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

Cancer Research and Treatment. 2020;52(2):374-387

Link1

Link2 Link3

A Phase II Trial of Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; Preliminary Results

Basem William, Ying Huang, Jonathan Brammer, Catherine Chung

Clinical Lymphoma Myeloma and Leukemia. 2019;19:S359-S360

Link1 Link2

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

Jung Yong Hong, Young Hyeh Ko, Shek-Ying Lin, Wing-Yan Au, Seok Jin Kim, Won Seog Kim, Moon Ki Choi, Qing-Ming Qing-Ming Yang, Silvia Park

OncoTargets and Therapy. 2014;1717

Link1

Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”

Marco Picardi, Claudia Giordano

Haematologica. 2021;106(4):1226-1227

Link1 Link2 Link3

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo

Haematologica. 2021;106(8):2277-2280

Link1 Link2 Link3

A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas

J. Maakaron, Y. Huang, J. Brammer, C. Chung, B. William

European Journal of Cancer. 2019;119:S28

Link1 Link2

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

Baoan Chen, Runzhe Chen

Drug Design, Development and Therapy. 2015;1729

Link1

A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMIDE (LEN) IN RELAPSED AND REFRACTORY (R/R) CUTANEOUS (CTCL) AND PERIPHERAL (PTCL) T-CELL LYMPHOMAS: PRELIMINARY RESULTS OF A PHASE II TRIAL

B.M. William, A. Abbasi, Y. Huang, R. Larbi, R. Giali, L. Yang, J. Brammer, C. Grantier, C. Hoffman, S. Ayyappan, R. Baiocchi, N. Epperla, B. Christian, L. Alinari, K. Maddocks, C. Chung

Hematological Oncology. 2019;37:471-472

Link1 Link2

BRENTUXIMAB VEDOTIN PLUS VIGEPP CHEMOTHERAPY FOR RELAPSED/REFRACTORY ADOLESCENT HODGKIN LYMPHOMA

N. Tsaplina, T. Valiev

Leukemia Research. 2022;121:S60

Link1 Link2

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

Robert Chen, Tanya Siddiqi, Sandra Thomas

Pharmacogenomics and Personalized Medicine. 2014;79

Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.